Vision Loss & GLP-1 Medications

Research published in peer-reviewed medical journals has identified a significant association between GLP-1 receptor agonist medications — particularly semaglutide (Ozempic, Wegovy, Rybelsus) — and an increased risk of developing NAION. Studies have shown that patients using these medications may face a substantially higher risk of NAION compared to the general population.

While the exact mechanism is still being studied, researchers believe GLP-1 medications may affect blood flow to the optic nerve, potentially through changes in blood pressure, vascular function, or rapid weight loss. The risk appears to be present across patients using GLP-1 drugs for both diabetes management and weight loss.

Lawsuits allege that the manufacturers of these medications knew or should have known about the vision loss risk and failed to adequately warn patients and prescribing physicians, depriving them of the ability to make informed decisions about their treatment.

Vision loss claims against GLP-1 drug manufacturers have been consolidated in MDL 3163 (In Re: Glucagon-Like Peptide-1 Receptor Agonists [GLP-1 RAs] Vision Injury Products Liability Litigation) in the Eastern District of Pennsylvania.

Approximately 54 cases are currently pending, with new cases continuing to be filed. This MDL is separate from the larger gastrointestinal injury litigation (MDL 3094), reflecting the distinct nature of the vision loss injuries.

The litigation is in its early stages. As scientific evidence continues to emerge and more affected patients come forward, the number of cases is expected to grow. No settlements have been reached yet, and bellwether trial scheduling is still being determined.